Background: Human retinal microvascular endothelial cells (HRMVECs) are involved in the pathogenesis of retinopathy of prematurity. In this study, the microRNA (miRNA) expression profiles of HRMVECs were investigated under resting conditions, angiogenic stimulation (VEGF treatment) and anti-VEGF treatment. Materials and methods: The miRNA profiles of HRMVECs under resting and angiogenic conditions (VEGF treatment), as well as after addition of aflibercept, bevacizumab or ranibizumab were evaluated by analyzing the transcriptome of small non-coding RNAs. Differentially expressed miRNAs were validated using qPCR and classified using Gene Ontology enrichment analysis. Results: Ten miRNAs were found to be significantly changed more than 2-fold. Seven of these miRNAs were changed between resting conditions and angiogenic stimulation. Four of these miRNAs (miR-139-5p/-3p and miR-335-5p/-3p) were validated by qPCR in independent experiments and were found to be associated with angiogenesis and cell migration in Gene Ontology analysis. In addition, analysis of the most abundant miRNAs in the HRMVEC miRNome (representing at least 1% of the miRNome) was conducted and identified miR-21-5p, miR-29a-3p, miR-100-5p and miR-126-5p/-3p to be differently expressed by at least 15% between resting conditions and angiogenic conditions. These miRNAs were found to be associated with apoptotic signaling, regulation of kinase activity, intracellular signal transduction, cell surface receptor signaling and positive regulation of cell differentiation in Gene Ontology analysis. No differentially regulated miRNAs between angiogenic stimulation and angiogenic stimulation plus anti-VEGF treatment were identified. Conclusion: In this study we characterized the miRNA profile of HRMVECs under resting, angiogenic and antiangiogenic conditions and identified several miRNAs of potential pathophysiologic importance for angioproliferative retinal diseases. Our results have implications for possible miRNA-targeted angiomodulatory approaches in diseases like diabetic retinopathy or retinopathy of prematurity.
Introduction
MicroRNAs (also known as miRNA or miR) are small, singlestranded, non-coding RNAs with a length of 18-25 nucleotides (Bartel, 2004) . By binding to their target mRNA, microRNAs can either induce degradation of the target mRNA or inhibit its translation (Agrawal and Chaqour, 2014; Bartel, 2004) . About one third of all protein coding genes are known miRNA targets (Lewis et al., 2005) . Moreover, a single miRNA can target multiple mRNAs and one mRNA can be targeted by several miRNAs (Meltzer, 2005) giving rise to complex regulatory networks.
Human retinal microvascular endothelial cells (HRMVECs) line the lumen of retinal blood vessels and are thus at the center of various retinal vascular diseases like proliferative retinopathy, diabetic macular edema or retinopathy of prematurity (ROP). Under pathologic conditions, HRMVECs can become overactivated by an excess of angiogenic https://doi.org/10.1016/j.exer.2019.01.006 Received 5 July 2018; Received in revised form 1 January 2019; Accepted 3 January 2019 mediators, like VEGF and IGF-1, and respond with increased vascular permeability and leakage of serum into the retina and by aberrant proliferation into the vitreous (Brzovic-Saric et al., 2015; Chen et al., 2011) . In these cases, intravitreally applied anti-VEGF substances are often used as treatment. While many effects of intraocular anti-VEGF therapy are well investigated, it is still unknown whether the application of anti-VEGF substances also affects the miRNA profile of HRMVECs. This is important because miRNAs are known angiogenic mediators (Landskroner-Eiger et al., 2013; Saif and Emanueli, 2014) and could be part of the pathomechanistic cascade driving (or inhibiting) angiogenic stimulation as suggested by Shen et al. in their study on the influence of miRNA on ocular neovascularization (Shen et al., 2008) . This study aims at investigating the changes in miRNA expression of HRMVECs caused by VEGF-mediated angiogenic stimulation. In addition, different anti-VEGF agents are used to analyse their impact on the miRNA profile of activated HRMVECs.
Materials and methods

Cultivation of human retinal microvascular endothelial cells (HRMVECs)
HRMVECs were obtained from Pelobiotech (Martinsried, Germany) and cultivated in Microvascular Endothelial Cell Growth Medium (MECGM; Pelobiotech, Martinsried, Germany) containing 5% FCS, glutamine, 0.5 ng/ml VEGF (vascular endothelial growth factor), 2 ng/ ml R3-IGF-1 (recombinant insulin-like growth factor-1), bFGF (basic fibroblast growth factor), hydrocortisone, antibiotics and EGF (epidermal growth factor) until confluence reached about 80%. Experiments for miRNA extraction were performed in technical triplicates using cells from passages 5 to 10.
Experimental setup
The miRNA profile of HRMVECs was characterized in five different conditions: 24 h of starvation (resting condition), 24 h of angiogenic stimulation (AS) as well as 12 h of angiogenic stimulation followed by 12 h of VEGF inhibition generated by addition of one of three different anti-VEGF substances (AS + aflibercept, AS + bevacizumab, AS + ranibizumab). A schematic drawing of the experimental setup is shown in Suppl. Figure 1 . In brief, at the beginning of each experiment dead cells and remaining growth medium were removed by washing the cell layer with Dulbecco's phosphate buffered saline (DPBS). Basal medium supplemented with 2% FCS (obtained from Pelobiotech to be from the same batch in all groups throughout the experiments) was added to the cells of the resting group to reduce cell activation while avoiding cell death, representing resting, unstimulated endothelium. Phase contrast microscopic control revealed that cells started to retract cell protrusions after a few hours incubation with these very low FCS concentrations (2% FCS), which is a sign for starting cell death. Therefore, medium was changed regularly and the FCS proportion was incrementally increased to 20% to allow cell survival under microscopic control, but aiming at keeping the FCS concentration in the resting group as low as possible. The remaining four groups were stimulated with growth medium additionally supplemented with 25 ng/ ml recombinant human VEGF (R&D Systems, catalogue number: 293-VE-010) to simulate angiogenic stimulation. Addition of VEGF is highly stimulative for endothelial cells, as shown by Ferrara et al. (2003) . The effect of VEGF on proliferation, cell migration, and vessel permeability are well described for different types of endothelial cells (Deissler et al., 2008) .
FCS was 5% in these groups throughout the course of experiments. After 12 h of angiogenic stimulation aflibercept, bevacizumab or ranibizumab were added to three of the four stimulated groups in a concentration corresponding to the one found in a human eye after standard intravitreal injection, assuming 4 ml vitreous volume and a standard injection volume of 50 μl anti-VEGF substance. After an additional 12 h incubation, the supernatant was removed in all groups, cells were washed twice with DPBS and then either lysed with lysis buffer from Macherey and Nagel (M&N, Düren, Germany) for library preparation by GenXPro (GenXPro, Frankfurt, Germany; (Muller et al., 2015) ) or using Quiazol lysis buffer (Qiagen, Germany) for qPCR. All groups were analyzed in biological triplicates.
miRNA library preparation and sequencing
After cell lysis, the small RNA fraction was extracted using the NucleoSpin ® miRNA kit from Macherey-Nagel. miRNA library preparation was done following the protocol by Müller et al. (Muller et al., 2015) : Size-selection (< 40 nt) was performed by polyacrylamide gel electrophoresis (PAGE) and precipitation. The resulting small RNA fraction was then linked to poly-N adapters (TrueQuant adapter, GenXPro GmbH), reversely transcribed (SuperScript III, Life Technologies) involving a polyadenylation step and amplified by PCR (KAPA HiFi Hot-Start Polymerase, KAPA Biosystems). A second size selection step of the enriched libraries by PAGE was followed by single-end sequencing (HiSeq2000, Illumina).
Sequencing data analysis
Adaptors were removed and duplicate reads based on PCR amplification eliminated with the TrueQuant Software (GenXPro, Germany). Data was transferred to the web-based open source platform Galaxy (Blankenberg et al., 2010; Giardine et al., 2005; Goecks et al., 2010) . Sequences were mapped to the human genome GRCh38/hg38 using the Bowtie2 tool (Galaxy version 0.6) (Langmead et al., 2009; Langmead and Salzberg, 2012) . Htseq-count (Galaxy version 0.6.1galaxy1) (Anders et al., 2015) was used to quantify overlaps between annotated reads and mature miRNAs from the online database miRBase (release 21) (http://www.mirbase.org). Comparison of the various groups for differential expression of mature miRNAs was performed by the DESeq2 algorithm (Galaxy version 2.1.8.0) (Love et al., 2014) . miRNAs showing statistically significant differential expressions between groups were obtained by filtering the Benjamini-Hochberg corrected p-value with a cutoff of ≤0.05. miRNAs showing at least a log 2-fold difference between groups were considered potentially relevant and were validated by qPCR. In addition, miRNAs that were highly expressed (at least 1% of the total miRNome) and changed by at least 15% between groups were also considered potentially relevant and were further analyzed. An overview of the data processing steps can be found in Suppl. Figure 2 . The sequencing data can be accessed at the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov), under the following accession numbers: PRJNA478816.
miRNA extraction for qPCR
All stimulation experiments were independently repeated three times to validate the sequencing results. miRNAs that were significantly and at least log 2-fold differentially expressed were verified by qPCR. For this purpose, miRNAs were extracted using the miRNeasy extraction kit (Qiagen, Hilden, Germany) following the manufacturer's instructions. In brief, 1 μg of total RNA was reverse transcribed with the miScript II RT Kit (Qiagen, Hilden, Germany) using the miScript HiSpec buffer. MiScript primers for let-7e-5p, miR-29a-3p, miR-139-5p/-3p, miR-192-5p, miR-194-5p , mimR-335-5p/-3p, miR-1248, miR-1291 and miR-4521 were purchased from Qiagen and used together with the miScript qPCR Kit (Qiagen) according to the manufacturer's instructions (see Suppl. Table 1 ). Annealing temperature was 55°C for all miRNAs except for hsa-miR-1291, which showed a double peak in the melting curve at 55°C. This miRNA was therefore quantified using an annealing temperature of 58°C. Hsa-let-7e-5p was used as housekeeping miRNA, since this miRNA was only minimally changed under different culture conditions according to the sequencing data, which was confirmed by qPCR (Suppl. Figure 3) . Analysis of qPCR data was performed using the ΔΔcT method in R (R Foundation, Vienna, Austria) (Livak and Schmittgen, 2001; Pfaffl, 2001; Zhang et al., 2013 ).
In silico analysis
miRNAs that were differentially expressed between groups were analyzed with regard to their validated targets using the online tool miRWalk 2.0 (http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2) (Dweep and Gretz, 2015) . After removal of duplicate miRNAs, miRNAs were further analyzed using a Gene Ontology enrichment analysis for biological processes (http://geneontology.org).
Results
miRNA profiling of HRMVECs
On average 4,549,693 ( ± 753,110) reads per sample could be matched to the human genome (GRCh38/hg38). Thereof 1,611,242 ( ± 343,231) reads were identified as copies of mature miRNA sequences. The 15 most abundantly expressed miRNAs are shown as reads per million (RPM) in Fig. 1 . Hsa-miR-21-5p accounted for almost 50% of the whole miRNome in all groups. All other highly expressed miRNAs represented less than 10% each of the total miRNome. In cells cultured under resting condition, 789 different miRNAs were identified, 818 in the group with angiogenic stimulation (AS) and 824, 821 and 852 respectively in the cells that were first angiogenically stimulated and then anti-VEGF treated by aflibercept, bevacizumab or ranibizumab. 67 miRNAs showed statistically significant differences in expression between resting and angiogenic conditions (Table 1) .
At least log 2-fold changed miRNAs
In accordance with Loscher et al. (2007) miRNAs that were not only statistically significantly regulated (p < 0.05) but also displayed a biologically relevant expression change (> log 2-fold) were further analyzed (Fig. 2) . MiRNAs hsa-miR-139-5p and hsa-miR-139-3p were relevantly higher expressed in all groups with angiogenic stimulation compared to resting condition -irrespective of the addition of anti-VEGF agents. The expression levels of miRNAs hsa-miR-29b-3p, hsamiR-192-5p, has-miR-194-5p, hsa-miR-335-5p and hsa-miR-335-3p were relevantly lower in all four groups with angiogenic stimulation compared to resting condition -also irrespective of the addition of anti-VEGF agents. In comparison to resting condition, the miRNAs hsa-miR-1248 and hsa-miR-1291 were lower expressed only in groups with angiogenic stimulation and addition of anti-VEGF agents. Validation by Fig. 1 . The 15 most abundantly expressed miRNAs in HRMVECs under resting condition (left) and under angiogenic stimulation (right). Each of the displayed miRNAs accounts for at least 1% of the total HRMVEC miRNome. Hsa-miR-21-5p was the most abundantly expressed miRNA in all groups accounting for almost 50% of the whole miRNome. Other highly expressed miRNAs represent max. 10% of the total miRNome. Shown is median and range (highest and lowest value). J.M. Walz et al. Experimental Eye Research 181 (2019) 98-104 qPCR confirmed these expression differences for miR-139-5p/3p and miR-335-5p/3p (see Suppl. Table 3 ).
Highly expressed (≥1% of the miRNome) and significantly regulated (≥15%) miRNAs
We identified several miRNAs that were highly expressed and at the same time differentially regulated between groups. For abundant miRNAs, the magnitude of expression level changes required to significantly alter protein levels, is difficult to predict. We chose to analyse all miRNAs that made up at least 1% of the total miRNome and were differentially expressed by at least 15%. The expression levels of three abundant miRNAs hsa-miR-21-5p, hsa-miR-29a-3p and hsa-miR-100-5p were lower with angiogenic stimulation compared to resting conditions, while the two abundant miRNAs hsa-miR-126-5p und hsa-miR-126-3p were higher expressed with angiogenic stimulation. Addition of VEGF inhibitors had no significant impact on the expression levels of these miRNAs (Fig. 3) .
In silico analysis of potential miRNA targets
All miRNAs validated by qPCR to be significantly regulated were further investigated using in silico analysis for their potential targets. For the two miRNAs miR-139-5p and miR-139-3p (both upregulated under angiogenic stimulation), miRWalk analysis revealed 159 validated target mRNAs. For miR-335-5p and miR-335-3p (both downregulated under angiogenic stimulation) miRWalk analysis found 2.760 validated target genes. 28 genes were found to be validated targets for all four miRNAs (Suppl. Figure 4a ). In addition, we analyzed those miRNAs that account for at least 1% of the total miRNome and differed in expression levels by at least 15% between groups. For miR-21-5p, miR-29a-3p and miR-100-5p (all downregulated under angiogenic stimulation), we identified 938 validated target genes. MiR-126-5p and -3p (upregulated under angiogenic stimulation) have a validated set of 145 target genes. 22 genes were found to be validated targets of all five abundantly expressed and regulated miRNAs (Suppl. Figure 4b) . A detailed list of regulated genes is provided in Suppl. Table 4 .
Gene Ontology (GO) enrichment analysis identified the targets of the significantly regulated miR-335-5p and -3p to be involved in regulation of angiogenesis and cell migration among others (Suppl. Table 5 ). The target genes of miR-139-5p and -3p as well as the 28 common targets of all four miRNAs did not map to any enriched biological processes.
For miR-100-5p, miR-21-5p and miR-29a-3p (all downregulated under angiogenic stimulation), GO analysis revealed that the most enriched biological process was "negative regulation of extrinsic apoptotic signaling pathway via death domain receptors" (7.15-fold; Suppl. Table 5 ). The targets of miR-126-5p and miR-126-3p (upregulated under angiogenic stimulation) were found to be mainly involved in "regulation of kinase activity" (3.62-fold) and the 22 common targets of all five abundantly expressed miRNAs mapped predominantly to processes involved in "positive regulation of cell differentiation" (8.35-fold; Suppl. Table 5 ).
Discussion
Until now the miRNA profile of HRMVECs has not been characterized despite the fact that miRNAs are involved in the regulation of many biological processes including angiogenesis. In oncology, miRNA profiles are already being used as biomarkers (Florczuk et al., 2017; Lai et al., 2017) and even therapeutic approaches targeting miRNA expression exist (Hinkel et al., 2014; Kolling et al., 2017) . In this study, we investigated the miRNA profile of HRMVECs under resting condition as well as under angiogenic stimulation with and without the presence of VEGF-inhibitors. Overall, we found the HRMVEC miRNome expression pattern to be rather robust. The strongest differences were observed between resting condition and angiogenic stimulation, while VEGF-inhibition for 12 h after previous angiogenic stimulation only induced minimal miRNome changes. It should be noted that media conditions differed between resting conditions (EC basal media + FBS) and angiogenic stimulation (EC growth media with supplements). Changes between these two groups might therefore not only be due to the addition of VEGF but also due to different culture media conditions. Groups with angiogenic stimulation and groups with angiogenic Fig. 2 . Overview of the ten miRNAs with statistically significant (p < 0.05) and relevant (> log 2-fold) modulation between groups. (next generation sequencing data; boxplots show the minimum and maximum value as well as the mean of three biological replicates).
J.M. Walz et al. Experimental Eye Research 181 (2019) 98-104 stimulation + anti-VEGF treatment were all cultured in EC growth media.
The results from our miRNome analysis concur strongly with data from Voellenkle et al. for HUVECs that were cultured under 1% O 2 or normoxia for 24 h (Voellenkle et al., 2012) . MiR-21-5p is the most predominant miRNA both in HUVECs and HRMVECs (accounting for more than 30% of miRNAs in both cell types). The second most abundant miRNA in HRMVECs (miR-126-3p) accounts for 6% of the total miRNome. In contrast to the HUVEC data by to be expressed at a rate of at least 1% of the total HRMVEC miRNome. This finding points at some potentially important differences between HUVECs and HRMVECs at the miRNA level and is in line with data from McCall et al. who compared miRNA expression in different types of endothelial cells (McCall et al., 2011) . Our results are in line with the results from Guduric-Fuchs et al. who have also found miR-21 as the most abundantly expressed miRNA in bovine retinal microvascular endothelial cells, next to miRNAs like miR-126, miR-106b, and let-7i, that were also highly expressed (Guduric-Fuchs et al., 2012) . The miRNA miR-34a-5p has not been described for endothelial cells previously and might be HRMVEC specific. The fact that independent RTqPCR reactions confirm a similar change in the two mature miRNAs from the same hairpin provides additional confidence. However, the results have to be seen with caution, as observed changes in the much more lowly expressed form may be biologically insignificant and just reflect the change in the more abundant form.
When comparing resting condition to angiogenic stimulation, we found several miRNAs to be differentially regulated in our HRMVEC cells. Two of these miRNAs (miR-21-5p and miR-126-5p) are well known as (pro-)angiomiRs (Wang and Olson, 2009) . Two other miRNAs (miR-335-5p and miR-21-5p) that showed reduced expression after angiogenic stimulation in our samples had been found to be lower in plasma samples from neovascular AMD patients compared to controls (Ertekin et al., 2014) . Interestingly, miR-139-3p showed higher expression under angiogenic stimulation in our samples and had been found exclusively in neovascular AMD patients but not in controls (Ertekin et al., 2014) . This association between our miRNA profiles and existing data of neovascular AMD patients, however, was not consistent for all miRNAs investigated, a fact that is not surprising given the complex and context-dependent regulation of miRNA expression (Doebele et al., 2010) . It has to be noted in this context that our resting condition represented a rather extreme condition.
When investigating the effect of anti-VEGF treatment on activated HRMVECs, we found surprisingly little differences although stochiometrically, the amount of anti-VEGF drugs was enough to bind all present VEGF assuming that two molecules ranibizumab bind one VEGF dimer (Hutton-Smith et al., 2016) , one molecule of aflibercept binds one VEGF dimer (Rudge et al., 2007) , and one molecule of bevacizumab binds two VEGF-dimers (MacDonald et al., 2016) . One possible reason might be the timing of our experimental setup. We used a setting in which angiogenic stimulation was present for 12 h followed by 12 h of VEGF inhibition. Other studies have used different settings with either addition of VEGF and VEGF-inhibitors at the same time (Yang et al., 2014a) or pre-incubation with VEGF-inhibitors before addition of VEGF (Yang et al., 2014b) . We have chosen a setting similar to Deissler et al. (2012) in order to mimic as closely as possible the clinical situation where VEGF-inhibitors are added to a condition with pre-existing high levels of VEGF and thus activated HRMVECs. In this setting, the effect of already bound VEGF cannot be neutralized by addition of soluble anti-VEGF drugs. In human patients, the effect of VEGF-inhibition can be observed rapidly after intravitreal injection. For example, in children with aggressive posterior retinopathy of prematurity (ROP), the effect of anti-VEGF treatment can be observed morphologically within the first 24 h (Travassos et al., 2007 ) which supports our model of miRNA analysis 12 h after addition of anti-VEGF agents. Other, more rapid changes in ROP, however, may not be modulated by miRNAs.
Comparing our results to other studies, in which miRNAs have been investigated in vivo in a functional model of ROP or in patients with aggressive posterior ROP (Metin et al., 2018) does not yield identical miRNA patterns. The reason might be that our experiments were done in a well defined cell culture surrounding, which is not directly comparable to the in vivo situation. Another point that needs to be considered is the fact that there is always a certain degree of variability during library preparation, which makes cross study comparisons difficult. The in silico analysis in our study revealed that the four miRNAs with statistical differences between groups (and validated by qPCR) had 28 common target genes. Among these target genes are for example IGF1 receptor, NOTCH1 and SOX4, genes with important roles in the cell cycle, cell proliferation, and growth. The five miRNAs which account for at least 1% of the total miRNome and display expression differences of at least 15% between groups had 22 common target genes. Among these target genes are for example Crk-like Fig. 3 . Differential expression of five identified miRNAs, that each made up at least 1% of the total miRNome and were regulated by at least 15% between groups (next generation sequencing data; boxplots show the minimal and maximal value as well as the mean of three biological replicates).
J.M. Walz et al. Experimental Eye Research 181 (2019) 98-104 protein, an activator of the Ras and Jun kinase signaling pathway, AGO2, involved in gene silencing, and MCYBP2, involved in cell proliferation. Combined this target gene pattern describes an intricate network of cellular processes in HRMVECs that is modulated by miRNA expression changes during angiogenic activation.
Conclusions
In summary, this is the first study to characterize the miRNA profile of HRMVECs under resting, angiogenic and anti-angiogenic conditions. We found the overall miRNome in HRMVECs to be a rather robust system with relatively few but possibly important miRNAs being differentially regulated. Our results have implications for possible miRNAtargeted angiomodulatory approaches in neovascular eye diseases like neovascular AMD, diabetic retinopathy and ROP.
